ストックスクリーナーアプリを入手
2.475
2.17%
-0.055
前日終値:
$2.53
開ける：
$2.55
24時間の取引高:
1.75M
Relative Volume:
0.37
時価総額：
$340.45M
収益：
-
当期純損益:
$-258.08M
株価収益率:
-0.90
EPS:
-2.75
ネットキャッシュフロー:
$-202.32M
1週間 パフォーマンス:
-5.89%
1か月 パフォーマンス:
-1.39%
6か月 パフォーマンス:
-79.43%
1年 パフォーマンス:
-88.50%
1日の値動き範囲:
$2.44
$2.58
1週間の範囲:
$2.44
$2.84
52週間の値動き範囲:
$2.19
$26.98
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
名前
Rocket Pharmaceuticals Inc
セクター
電話
646-440-9100
住所
350 FIFTH AVENUE, NEW YORK, NY
RCKT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
2.475 | 340.45M | 0 | -258.08M | -202.32M | -2.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.00 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.16 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.33 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.02 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.15 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-30 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2025-05-28 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-05-28 | ダウングレード | Jefferies | Buy → Hold |
| 2025-05-28 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-05-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-27 | ダウングレード | Needham | Buy → Hold |
| 2025-05-27 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-03-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-12-30 | 開始されました | Wedbush | Outperform |
| 2024-12-18 | 開始されました | Jefferies | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2023-10-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-01 | 開始されました | Morgan Stanley | Overweight |
| 2022-11-08 | 開始されました | Canaccord Genuity | Buy |
| 2022-11-01 | 開始されました | BTIG Research | Buy |
| 2022-07-08 | 開始されました | Raymond James | Outperform |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2021-02-18 | 開始されました | Needham | Buy |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-12-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-07-02 | 開始されました | JP Morgan | Overweight |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-06-01 | 再開されました | Oppenheimer | Outperform |
| 2019-11-06 | 開始されました | Chardan Capital Markets | Buy |
| 2019-09-26 | 開始されました | Piper Jaffray | Overweight |
| 2019-04-23 | 開始されました | Robert W. Baird | Outperform |
| 2019-03-15 | 開始されました | BofA/Merrill | Buy |
| 2019-02-05 | 開始されました | Oppenheimer | Outperform |
| 2018-09-13 | 開始されました | Ladenburg Thalmann | Buy |
| 2018-07-10 | 開始されました | William Blair | Outperform |
すべてを表示
Rocket Pharmaceuticals Inc (RCKT) 最新ニュース
Investors who lost money with shares of Rocket Pharmaceuticals, - openPR.com
Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Benzinga
Rocket Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - FinancialContent
Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $5.00 at UBS Group - Defense World
RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire
Rocket Pharmaceuticals (RCKT) Price Target Lowered by Analyst | - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - PR Newswire
UBS Cuts Price Target on Rocket Pharmaceuticals to $5 From $12, Maintains Buy Rating - MarketScreener
UBS Adjusts Price Target for Rocket Pharmaceuticals (RCKT) Amid Program Developments | RCKT Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. LawsuitRCKT - PR Newswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire
Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph
Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your RightsRCKT - GuruFocus
Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025 - ACCESS Newswire
Recover Investment Losses: Levi & Korsinsky Files Class Action Against Rocket Pharmaceuticals, Inc. (RCKT) - ACCESS Newswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - marketscreener.com
RCKT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
RCKT Investor Notice: Robbins LLP Reminds Shareholders of - GlobeNewswire
Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead By Investing.com - Investing.com South Africa
Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead - Investing.com Australia
RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
ROSEN, A LEADING LAW FIRM, Encourages Rocket - GlobeNewswire
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ROCKET ALERT: Bragar Eagel & Squire, P.C. Announces that a - GlobeNewswire
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Urged to Join Class Action Before August 11, 2025Contact Levi & Korsinsky - ACCESS Newswire
ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - TradingView
RCKT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - ACCESS Newswire
Contact Levi & Korsinsky by August 11, 2025 Deadline to - GlobeNewswire
RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Business Wire
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA's Clinical Hold on Gene Therapy TrialHagens Berman - PR Newswire
Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc.(RCKT) - PR Newswire
Join Class Action to Recover Losses From Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky Before August 11, 2025 - ACCESS Newswire
Join Class Action to Recover Losses from Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky Before August 11, 2025 - ACCESS Newswire
Shareholder Alert: Robbins LLP Informs Investors of the Rocket Pharmaceuticals, Inc. Class Action - Eastern Progress
RCKT INVESTOR ALERT: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Rocket Pharmaceuticals Class Action Lawsuit - PR Newswire
August 11, 2025 Deadline Approaching: Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)Contact Levi & Korsinsky - ACCESS Newswire
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class - GlobeNewswire
Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial – Hagens Berman - TradingView
Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
Rocket Pharmaceuticals, Inc. (RCKT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - GlobeNewswire
Securities Fraud Class Action Filed Against Rocket Pharmaceuticals, Inc. (RCKT)Levi & Korsinsky Reminds Investors of August 11, 2025 - ACCESS Newswire
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
RCKT’s 2023 Market Dance: Down -73.91% – Time to Invest? - investchronicle.com
Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Bought by California State Teachers Retirement System - Defense World
Cantor Fitzgerald Forecasts RCKT FY2026 Earnings - Defense World
Rocket Pharmaceuticals Inc (RCKT) 財務データ
収益
当期純利益
現金流量
EPS
Rocket Pharmaceuticals Inc (RCKT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schwartz Jonathan David | See Remarks |
May 20 '25 |
Sale |
6.45 |
801 |
5,163 |
235,255 |
| Patel Kinnari | See Remarks |
May 20 '25 |
Sale |
6.45 |
767 |
4,944 |
441,927 |
| Shah Gaurav | CEO |
May 20 '25 |
Sale |
6.45 |
2,253 |
14,523 |
786,806 |
| Wilson Martin | General Counsel |
May 20 '25 |
Sale |
6.45 |
587 |
3,784 |
149,163 |
| Militello John | See Remarks |
May 16 '25 |
Sale |
6.53 |
655 |
4,276 |
64,384 |
| Patel Kinnari | See Remarks |
May 16 '25 |
Sale |
6.53 |
1,409 |
9,198 |
442,694 |
| Schwartz Jonathan David | See Remarks |
May 16 '25 |
Sale |
6.53 |
1,582 |
10,327 |
236,056 |
| Shah Gaurav | CEO |
May 16 '25 |
Sale |
6.53 |
3,621 |
23,638 |
789,059 |
| Wilson Martin | General Counsel |
May 16 '25 |
Sale |
6.53 |
946 |
6,175 |
149,750 |
0.39%
0.26%
大文字化:
|
ボリューム (24 時間):